Bioceltix aims to market drugs for animals (dogs, horses and cats), containing Mesenchymal Stem Cells (MSC) as an active pharmaceutical ingredient and based on certified production technology in the pharmaceutical quality standard cGMP (Current Good Manufacturing Practice). The company's business model is based on sales through a partnership chain with rights to develop medical products as well as production of drugs in its own plant that operates under the pharmaceutical quality standard. Product rights can be purchased by concluding partnership, license or distribution agreements.
Headquarters
ul. Bierutowska 57-59
Wroclaw; Dolnoslaskie;
Postal Code: 51-317
Contact Details: Purchase the Bioceltix S.A. report to view the information.
Website: http://www.bioceltix.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service